A new comprehensive review published in *BMJ* suggests that many individuals who discontinue popular weight-loss medications may regain lost weight within two years, raising questions about the long-term sustainability of pharmaceutical interventions for obesity.The findings come as prescriptions for drugs like Ozempic, Wegovy, and Mounjaro have surged in recent months, driven by both patient demand and increased physician recommendations. This research underscores the importance of realistic expectations and ongoing discussion between patients and their doctors regarding the potential need for continued treatment too maintain weight loss .
Individuals who stop taking weight-loss medications are likely to regain their lost weight within two years, a comprehensive review of numerous studies has found. The research, published in the journal BMJ, examined the long-term effects of these drugs.
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro have gained significant popularity due to their demonstrated effectiveness in regulating appetite and promoting weight reduction. However, the new findings suggest that maintaining that weight loss requires continued use of the medication.
Researchers analyzed data from a substantial number of studies to reach their conclusions. The review indicates that, on average, individuals tend to return to their original weight within approximately two years after discontinuing the medications. This highlights the ongoing challenge of weight management and the potential need for long-term pharmacological intervention for some individuals.
The findings underscore the importance of considering the long-term implications of weight-loss medications and the potential for weight regain if treatment is stopped. This information is crucial for both patients and healthcare providers as they develop and implement weight management plans.
